

Attorney Docket No.: 10583.204-US

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Ye et al.

Confirmation No: To be assigned

Serial No.: TBA

Group Art Unit: To be assigned

Filed: July 6, 2006

Examiner: To be assigned

For: Amylase

## INFORMATION DISCLOSURE STATEMENT (IDS) UNDER 37 CFR 1.97(b)

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In accordance with 37 C.F.R. 1.56, 1.97 and 1.98, Applicants submit herewith references which may be material to the patentability of this application and with respect to which there may be a duty to disclose. While the references may be material under 37 C.F.R. 1.56, it is not intended to constitute an admission that the references are prior art. The filing of this IDS shall not be construed as a representation that no other material references than those listed exist or that a search has been conducted.

The references are listed in Form PTO/SB/08A, which is in accordance with the requirements of M.P.E.P. 609. A copy of the references is enclosed.

This IDS is being filed **within** three months of the filing date of a national application or date of entry into the national stage of an international application, or **before** the mailing date of a first Office action on the merits, or **before** the mailing date of a first Office action after the filing of a request for continued examination. Therefore, no fee is due.

Respectfully submitted,

Date: July 6, 2006

Jaşøn I. Garbell, Reg. No. 44,116 Novozymes North America, Inc. 500 Fifth Avenue, Suite 1600 New York, NY 10110

(212)840-0097

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE collection of information unless it contains a valid OMB control number.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Under the Par	perwork Reduction /	act of 1995, no perso	ins are required to n	espond to a collection of information unles	ss it contains a valid UMB control number.		
Substitute for	or form 1449A/PTO			Compl	Complete if Known / [ ]		
				Application Number	<b>基別/ラウブしとし</b>		
	INFORMAT	ION DISCLOSU	JRE	Filing Date	July 6, 2006		
STATEMENT BY APPLICANT (use as many sheets as necessary)			ANT	First Named Inventor	Ye et al.		
				Art Unit	To be assigned		
				Examiner Name	To be assigned		
Sheet	1	of	2	Attorney Docket Number	10583.204-US		

U.S PATENT DOCUMENTS						
Examiner Initials	Cite No. 1	Document Number  Number - Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
			·			

FOREIGN PATENT DOCUMENTS							
Examiner Initials	Cite No. 1	Foreign Patent Document  Country Code <sup>3</sup> – Number <sup>4</sup> – Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>	
	1	WO 91/04669	04-18-1991	Novo Nordisk A/S			
		WO 96/01323	01-18-1996	Danisco			
		WO 03/016535	02-27-2003	DSM			
		WO 03/083054	10-09-2003	Diversa			
	ļ						
	<del>                                     </del>						
	<del> </del>						
	-						
	1						
	1						
	ļ						
	ļ						
	<del> </del>						
	i	l			l	L	

Examiner	Date	
Signature	Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner of Patents, Washington, DC 20231.

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

## AP20 Rec'd PCT/PTO 08 JUL 2006

PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Pap	erwork Reduction	Act of 1995, no pers	ons are required to	respond to a collection of information unles		
Substitute for form 1449A/PTO				Complete if Known 0 1 0 5 4 2		
				Application Number	「略し/クロンした」	
	INFORMAT	TON DISCLOS	URE	Filing Date	July 6, 2006	
	STATEMENT BY APPLICANT (use as many sheets as necessary)			First Named Inventor	Ye et al.	
				Art Unit	To be assigned	
				Examiner Name	To be assigned	
Sheet	2	of	2	Attorney Docket Number	10583.204-US	

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS								
Examiner's Initials	Cite No. 1 Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published							
		Swift, HJ et al, STRUCTURE AND MOLECULAR MODEL REFINEMENT OF ASPERGILLUS ORYZAE (TAKA) ALPHA-AMYLASE: AND APPLICATION OF THE SIMULTED-ANNEALING METHOD, (1992)						
		Gaupta et al, MICROBIAL ALPHA-AMYLASE: A BIOTECHNOLOGICAL PERSPECTIVE, Vol. 38, Part 11, pages 1599-1616 (2003)						
,								

Examiner	Date	
Signature	Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner of Patents, Washington, DC 20231.

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.